Skip to main content

Peer Review reports

From: SPIOMET4HEALTH—efficacy, tolerability and safety of lifestyle intervention plus a fixed dose combination of spironolactone, pioglitazone and metformin (SPIOMET) for adolescent girls and young women with polycystic ovary syndrome: study protocol for a multicentre, randomised, double-blind, placebo-controlled, four-arm, parallel-group, phase II clinical trial

Original Submission
3 Aug 2023 Submitted Original manuscript
11 Aug 2023 Reviewed Reviewer Report - Kirsty Loudon
15 Aug 2023 Author responded Author comments - Cristina Garcia-Beltran
Resubmission - Version 2
15 Aug 2023 Submitted Manuscript version 2
Publishing
17 Aug 2023 Editorially accepted
15 Sep 2023 Article published 10.1186/s13063-023-07593-6

You can find further information about peer review here.

Back to article page